Cetuximab is a monoclonal antibody targeting the transmembrane receptor HER-1 (epidermal growth factor receptor, EGFR). In theory, inhibition of EGFR may influence tumor behavior since the receptor regulates many important tumor cell activities including tumor growth, angiogenesis, and inhibition of the apoptotic response to chemotherapy and radiotherapy. Available experimental data suggest that cetuximab may enhance the activity of chemotherapy and radiotherapy, reverse resistance to some anticancer drugs, and has itself anticancer activity. Early clinical data support the experimental results. This paper reviews the published findings on cetuximab in the treatment of advanced head and neck cancer and points out the future objectives of the clinical research on this drug. (Int J Biol Markers 2007; 22 (suppl 4): S71-6)
INTRODUCTION
The epidermal growth factor receptor (EGFR) is overexpressed in most head and neck cancers (HNC), as well as in the dysplastic areas and the normal mucosa surrounding the tumor. Overexpression in the non-neoplastic areas suggests an important role of EGFR in the development of HNC, which is maintained in the natural history of the disease. Overexpression of EGFR in squamous cell carcinoma of the head and neck (SCCHN) is associated with more aggressive disease, increased resistance to chemotherapy and radiotherapy, increased metastasis, inhibition of apoptosis, promotion of angiogenesis, and, finally, poor prognosis and decreased survival (1) (2) (3) (4) (5) (6) (7) (8) .
The effect of receptor blockade by the monoclonal antibody cetuximab confirms its functions. Indeed, blockade of EGFR results in the inhibition of DNA damage repair mechanisms, cell cycle arrest at late G1, inhibition of angiogenesis, and restoration of the apoptotic response, enhancing the antitumor effects of chemotherapy and radiotherapy (9) (10) (11) .
A number of preclinical studies have confirmed that the monoclonal antibody cetuximab potentiates the cytotoxic effects of chemotherapy and radiotherapy (12, 13) . On this basis cetuximab entered clinical evaluation in association with radiotherapy and chemotherapy and as single agent against advanced squamous cell carcinomas of the head and neck.
CETUXIMAB AND RADIOTHERAPY
Robert et al, in a phase I study, evaluated the administration of escalating doses of cetuximab with concur-rent radiotherapy (14) . The drug was given at doses ranging from 100 to 500 mg/m 2 (loading dose) and from 100 to 250 mg/m 2 (weekly maintenance dose) to patients with locally advanced HNC. All patients achieved objective responses (100%) and response was complete in most cases. Interestingly, the expected response rate in patients with similar stage HNC treated with radiotherapy alone, based on historical data, is much lower, ranging between 31% and 46% (15) . Cetuximab did not worsen the common radiotherapy side effects, adding only mild to moderate skin reactions. However, one patient was removed from the study because of the development of an anaphylactic reaction. Robert's trial showed that cetuximab at the standard doses (400 mg/m 2 loading dose and 250 mg/m 2 weekly maintenance dose) can be safely combined with radiotherapy without any dose-limiting toxicity. The observed activity seems to confirm the strong rationale of combining cetuximab and radiotherapy.
Bonner et al conducted a phase III study in which 424 previously untreated patients with locoregionally advanced HNC were randomly assigned to receive radiotherapy with or without weekly cetuximab at standard clinical doses. This study was recently published (16) . Thirteen patients discontinued cetuximab mostly because of hypersensitivity reactions (4 patients) or acneiform rash (8 patients). Apart from these toxicities, moderate and severe reactions were similar in the 2 treatment arms, confirming that cetuximab does not increase the common side effects of radiotherapy (Tab. I). The experimental arm showed significant improvement in locoregional control ( Fig. 1 ) and in median survival ( Fig. 2 ): 24.4 vs 14.9 months (p<0.005) and 49 vs 29.3 months (p<0.03), respectively, compared to radiotherapy alone.
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This is the first trial showing that the results of radiotherapy can be significantly improved by the addition of a drug without worsening radiotherapy toxicity. The weakness of Bonner's trial is the chosen control arm, radiotherapy alone. Four meta-analyses have shown that chemoradiation is the standard treatment for advanced unresectable SCCHN (17) . At present, most SCCHN patients are not treated with radiotherapy alone; radiotherapy remains the treatment of choice only when adequate clinical expertise is not available or in any other situation precluding chemotherapy. Bonner's trial suggests that in the above conditions, precluding chemoradiation, the combination of cetuximab and radiotherapy could be considered as a new standard. However, it must be stressed that it is unclear whether cetuximab is as effective as chemotherapy combined with radiotherapy, and it should therefore not be used as an alternative when chemoradiation is possible.
CETUXIMAB AND CHEMOTHERAPY
Palliative chemotherapy showed an advantage in quality of life and a possible improvement in survival over best supportive care in recurrent or metastatic HNC (18) (19) (20) . However, responses are rare and complete responses are extremely rare. Eventually all patients will experience disease progression and will ultimately die of their disease. Due to the poor outcome of these patients there is a clear need for new active agents. Cetuximab is a new, attractive compound for palliation of advanced HNC. Its different mechanism of action with respect to chemotherapy, the lack of crossresistance, and the limited side effects make it a good partner for patients with poor performance status. In a phase II study Trigo et al (21) evaluated the administration of cetuximab alone in 103 patients refractory to cisplatin-based chemotherapy. Seventeen patients achieved an objective response including 5 complete responses and a median survival of 5.9 months. These results are similar to those obtained with platinum alone in chemotherapy-naïve patients (22) . The most common adverse event was skin rash or acne reaction, which occurred in 80% of patients. There was 1 treatment-related death due to a hypersensitivity reaction.
The activity and the mild toxicity profile of cetuximab induced researchers to explore the combination of the monoclonal antibody with chemotherapy. The first report dealt with a phase I study in which cetuximab was combined with cisplatin to determine the safety profile, the optimal biological dose, the maximum tolerated dose and the pharmacological profile of cetuximab alone and in combination with cisplatin (23) . The safety of cetuximab, alone or in combination with chemotherapy, was tested in 3 phase I trials in which the monoclonal antibody was delivered as single dose, weekly multiple dose, and weekly multiple dose with cisplatin. Bourhis evaluated the administration of cetuximab in association with cisplatin, or carboplatin and fluorouracil. The treatment proved to be tolerable, allowing the administration of the planned dose of cytotoxic drugs thanks to the lack of overlapping toxicities (24). Thus, cetuximab can be safely added to chemotherapy and improve its results without worsening toxicity. Based on these findings, Burtness et al conducted a phase III trial comparing cisplatin with cetuximab (arm A) or placebo (arm B) (25) . The combination arm experienced more neutropenia, hypomagnesemia and skin toxicity. In particular, cutaneous side effects were present in 77% of patients in arm A (grade 3 23%) and 24% in arm B (no grade 3). Hypersensitivity was recorded in both arms: 3% grade 3 and 3% grade 4 in arm A and 2% grade 3 in arm B (Tab. II). The combination of cetuximab and chemotherapy gave a higher response rate than placebo (26% vs 10%). The response Grade 3-5 adverse events occurring in more than 5% of patients Two deaths occurred on study, one secondary to pneumonia* and one from an unknown cause. Modified from Pfister et al (30) rate for patients in arm A who developed skin toxicity was 33% compared to 7% in patients who did not. Although this difference is not significant, skin toxicity was associated with a statistically significant survival improvement (p=0.01). Progression-free survival (PFS) and overall survival (OS) showed a trend in favor of arm A without reaching statistical significance. The study demonstrated that cetuximab is able to increase the activity of chemotherapy and that skin reaction is correlated with improvement in survival. Also Saltz et al (26) described the relationship between skin rash and prolonged survival in an earlier report. Another way to use cetuximab derives from the relationship between EGFR overexpression and drug resistance. EGFR phosphorylation results in the activation of multiple pathways including PI3K-AKT, which enhances Bcl-2 activity and inhibits the apoptotic response to chemotherapy and radiotherapy. Thus, inhibition of EGFR should downregulate Bcl-2 activity, restoring the apoptotic response to chemotherapy and radiotherapy (9, 10, 27) . This is why cetuximab has been associated with some cytotoxic drugs to treat patients who were refractory to the same drugs.
Herbst et al treated with cetuximab and cisplatin SCCHN patients who did not respond to or progressed under cisplatin/paclitaxel or cisplatin/fluorouracil chemotherapy (28) . Patients were divided into 3 groups according to the response to the previous chemotherapy regimen: group 1, stable disease; group 2, disease progression during treatment; group 3, progression within 90 days of the end of chemotherapy. Patients were treated with cetuximab at the conventional dose and cisplatin at a dose of 75 or 100 mg/m 2 every 3 weeks. Cetuximab did not show any effects on the pharmacokinetic profile of cisplatin and the toxicity of cisplatin was not exacerbated by cetuximab. The objective response rates were 18%, 20% and 6%, respectively, in the 3 groups. The PFS and OS were longer in group 1 (4.2 and 11.7 months) than in group 2 (3 and 6.1 months) and group 3 (2 and 4.3 months).
Baselga et al (29) treated 96 platinum-refractory patients with cetuximab and cisplatin or carboplatin every 3 or 4 weeks. The response rate was 10%, with a disease control rate of 53%. The median time to progression (TTP) and OS were 85 and 183 days, respectively. There was a trend towards longer TTP and OS in partial responders and, similarly, in patients treated with the every 3 weeks schedule compared to every 4 weeks. Skin reactions and acne-like rash were the most common adverse events, occurring in 80% and 72% of patients, respectively. Patients who developed grade 1 or 2 skin reactions had a longer TTP and OS.
These studies demonstrate that cetuximab can reverse cisplatin resistance in a small but significant group of patients without increasing the expected toxicity.
CETUXIMAB AND CHEMORADIATION
As stated above, chemoradiation is the standard of care for most patients with SCCHN, but data on cetuximab combined with chemoradiation are lacking. At present there are many unanswered questions on this matter. First of all we do not know whether cetuximab combined with radiotherapy may be an alternative to chemoradiation. We cannot answer this question unless a comparative randomized trial is performed. To our knowledge, there are no such trials ongoing.
The second question is whether cetuximab may improve chemoradiation in terms of the major end points: overall survival, disease-free survival and complete response. This second question is more complex and requires multilevel evaluation. The first level is to establish whether the combination of cetuximab with chemoradiation is safe. The second is to determine the appropriate dosage and scheduling. The third is to establish whether the degree of activity of the combination may be interesting for future phase III trials. Should this be the case, the last step is to compare chemoradiation with chemoradiation plus cetuximab in a randomized setting.
To date only Pfister et al have published a trial of chemoradiation combined with cetuximab in a full paper (30) . All the evaluable patients entering this study achieved an objective response, but 2 grade V events occurred. The investigators considered the relationship between the 2 deaths on treatment and the investigational regimen uncertain. However, additional nonfatal but significant adverse events occurred, leading the authors to close the trial in advance. The major toxicities encountered by Pfister et al are listed in Table III . The long-term analysis of the treated population showed that at 3 years' median follow-up, the PFS and OS were 56% and 76%, respectively, suggesting a favorable effect of the addition of cetuximab. The authors concluded that the search for a less toxic regimen combining cetuximab and chemoradiation is highly recommended.
Our own group reported in abstract form on an ongoing experience of rapidly alternated chemoradiation and cetuximab (31) . Alternating chemoradiation is a minor variation of concurrent chemoradiation aimed at reducing the toxicity (32) . This is why we are using this approach in a phase II trial of combined chemoradiotherapy and cetuximab. At present, 24 patients have been accrued and 13 are fully evaluable. No major toxicity occurred and all patients achieved objective responses, 10 of which were complete. This study has a planned accrual of 45 patients; the final analysis is therefore expected within 2007. Other phase II studies of chemoradiation and cetuximab are in progress worldwide and the results of some of these are expected soon. Notwithstanding the lack of definitive data from phase II studies, the RTOG has designed and activated a phase III trial of chemoradiation plus or minus cetuximab (33) . Data will be available in the forthcoming years.
At the moment the true role of the combination of cetuximab and chemoradiation in SCCHN is not understood due to the lack of definitive data. This treatment must therefore be regarded as an experimental approach not to be used outside of clinical trials.
CONCLUSIONS
Cetuximab is the first monoclonal antibody showing clinical activity in SCCHN. The published data support its use in patients who are refractory to platinum/fluorouracil or platinum/paclitaxel combinations. Preliminary data also suggest that cetuximab can be given in combination with cisplatin in chemotherapy-naïve patients, with a positive impact on response rates. If cetuximab will be added to more standard palliative chemotherapy, i.e., cisplatin and paclitaxel or cisplatin and fluorouracil, the benefit could possibly be more evident. Moreover, further investigations should take into account the end point "quality of life" by systematically including the use of validated questionnaires.
Convincing published data support the use of cetuximab in combination with radiotherapy, but due to the lack of comparative trials, this approach should be restricted to patients who are not eligible for chemoradiation. The results of Bonner's trial showed not only significant improvements in all the major end points, but also that radiotherapy toxicity remained unchanged notwith-standing the addition of cetuximab. No randomized phase III studies comparing chemoradiation and cetuximab plus radiation have yet been carried out, but considering that chemoradiation is much more toxic than radiation alone, such trials are highly recommended.
Finally, the combination of cetuximab and chemoradiotherapy is almost completely uninvestigated. The only published trial recorded 2 on-treatment deaths, but their relationship to the addition of cetuximab is unclear. Other preliminary data from ongoing studies do not show any significant worsening of toxicity. However, the available data are inadequate to suggest the use of cetuximab during a chemoradiotherapy program outside clinical trials.
In conclusion, cetuximab is an important new drug in the management of HNC. Clinical investigations on cetuximab are still ongoing. Additional advantages of the introduction of cetuximab in daily clinical practice can therefore be expected in the future.
